AUO Perioperative Use of Pembrolizumab plus Enfortumab Vedotin in Muscle-invasive Bladder Carcinoma

被引：0
|
作者：
Rexer, H. [1 ]
Merseburger, A. [2 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Deutsch Krebsgesell eV, Organgruppensprecher Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGIE | 2023年 / 62卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1262 / 1263
页数：2
相关论文
共 50 条
  • [41] Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
    Funt, Samuel A.
    Rosenberg, Jonathan E.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (04) : 221 - 234
  • [42] Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial
    Teo, Min Yuen
    Rosenberg, Jonathan E.
    UROLOGIC CLINICS OF NORTH AMERICA, 2018, 45 (02) : 287 - +
  • [43] Chemotherapy for muscle-invasive bladder cancer in the perioperative setting: Current standards
    Dreicer, Robert
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (01) : 72 - 75
  • [44] Systemic, perioperative management of muscle-invasive bladder cancer and future horizons
    Samuel A. Funt
    Jonathan E. Rosenberg
    Nature Reviews Clinical Oncology, 2017, 14 : 221 - 234
  • [45] FDA OKs Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2024, 30 (02):
  • [46] A Role for Neoadjuvant Gemcitabine Plus Cisplatin in Muscle-Invasive Urothelial Carcinoma of the Bladder A Retrospective Experience
    Dash, Atreya
    Pettus, Joseph A.
    Herr, Harry W.
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Russo, Paul
    Boyle, Mary G.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    CANCER, 2008, 113 (09) : 2471 - 2477
  • [47] Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation
    Sternberg, Cora N.
    SEMINARS IN ONCOLOGY, 2007, 34 (02) : 122 - 128
  • [48] Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
    Huang, Haijun
    Zhang, Yucong
    Chen, Zhi
    Zeng, Xing
    Hu, Zhiquan
    Yang, Chunguang
    HELIYON, 2023, 9 (04)
  • [49] FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
    Maguire, William F.
    Lee, Daniel
    Weinstock, Chana
    Gao, Xin
    Bulik, Catharine C.
    Agrawal, Sundeep
    Chang, Elaine
    Hamed, Salaheldin S.
    Bloomquist, Erik W.
    Tang, Shenghui
    Pazdur, Richard
    Kluetz, Paul G.
    Amiri-Kordestani, Laleh
    Suzman, Daniel L.
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2011 - 2016
  • [50] Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Hong
    Li, Shan
    Yuan, Dan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
12345